

GLAXOSMITHKLINE PLC

Form 6-K

February 06, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 06th February 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Sir Philip Hampton  
 b) Position/status Non-Executive Chairman

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £14.95 2,926.421

d) Aggregated information  
 Aggregated volume Price n/a (single transaction)

e) Date of the transaction 2019-02-06

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr Vindi Banga  
 b) Position/status Senior Independent Non-Executive Director

c) Initial notification/  
 amendment Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018.

- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£14.95	480.769
- d) Aggregated information  
Aggregated volume Price n/a (single transaction)
- e) Date of the transaction 2019-02-06
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr Vivienne Cox
- b) Position/status Independent Non-Executive Director
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument

Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent	
b) Nature of the transaction	Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018.	
c) Price(s) and volume(s)	Price(s) £14.95	Volume(s) 355.351
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2019-02-06	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms Lynn Elsenhans  
b) Position/status Independent Non-Executive  
Director

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type  
of instrument; (ii) each type of transaction; (iii) each date; and (iv)  
each place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares  
(‘ADSs’)  
ISIN: US37733W1053

b) Nature of the transaction Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018.

c) Price(s) and volume(s) Price(s) Volume(s)  
\$39.27 1,049.907

d) Aggregated information Aggregated volume Price n/a (single transaction)

e) Date of the transaction 2019-02-06

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr Laurie Glimcher  
b) Position/status Independent Non-Executive Director

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

American Depositary Shares ('ADSs')  
ISIN: US37733W1053

a) Description of the financial instrument

b) Nature of the transaction Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018.

c) Price(s) and volume(s)	Price(s) \$39.27	Volume(s) 1,399.876
d) Aggregated information Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2019-02-06	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Dr Jesse Goodman
b) Position/status	Independent Non-Executive Director

c) Initial notification/ amendment	Initial notification
---------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

American Depositary Shares ('ADSs')  
ISIN: US37733W1053

a) Description of the financial instrument

b) Nature of the transaction	Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018.
------------------------------	---

c) Price(s) and volume(s)	Price(s) \$39.27	Volume(s) 422.376
d) Aggregated information Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2019-02-06	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms Judy Lewent
  - b) Position/status Independent Non-Executive Director
  - c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

American Depositary Shares ('ADSs')  
ISIN: US37733W1053

- a) Description of the financial instrument

- b) Nature of the transaction Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018.

- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
\$39.27	470.648
- d) Aggregated information Aggregated volume Price n/a (single transaction)
- e) Date of the transaction 2019-02-06
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr Urs Rohner
  - b) Position/status Independent Non-Executive Director
  - c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2018 to 31 December 2018.

- |                             |                          |           |
|-----------------------------|--------------------------|-----------|
| c) Price(s) and volume(s)   | Price(s)                 | Volume(s) |
|                             | £14.95                   | 480.769   |
| d) Aggregated information   | n/a (single transaction) |           |
| e) Date of the transaction  | 2019-02-06               |           |
| f) Place of the transaction | n/a                      |           |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



GlaxoSmithKline plc  
(Registrant)

Date: February 06th, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc